Press releases
- Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
- Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
- Mirum Pharmaceuticals’ LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
- Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
- Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum’s LIVMARLI
- Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
- Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
More ▼
Key statistics
On Tuesday, Mirum Pharmaceuticals Inc (MIRM*:MEX) closed at 479.15, 0.00% above its 52-week low of 479.15, set on Jan 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 479.15 |
---|---|
High | 479.15 |
Low | 479.15 |
Bid | 403.39 |
Offer | -- |
Previous close | 433.65 |
Average volume | 0.00 |
---|---|
Shares outstanding | 47.12m |
Free float | 45.37m |
P/E (TTM) | -- |
Market cap | 1.22bn USD |
EPS (TTM) | -4.08 USD |
Data delayed at least 20 minutes, as of Jan 09 2024 11:30 GMT.
More ▼